Back to Search
DONALD DE ALWIS, MD
MD
Student in an Organized Health Care Education/Training Program
NPI: 1235925298Individual
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training ProgramPrimary
Student in an Organized Health Care Education/Training Program
Code: 390200000X
Research & Publications (18)
Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice.
PMID 18039567·Eur J Cancer·2008
7-preclinical
The true face of the revolution in oncology drug development: a personal reflection.
PMID 18690853·Curr Clin Pharmacol·2007
8-other
Statistical methods in media optimization for batch and fed-batch animal cell culture.
PMID 17242929·Bioprocess Biosyst Eng·2007
7-preclinical
A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours.
PMID 17146732·Invest New Drugs·2007
3-trial
Acute subretinal macular haemorrhage following an accidental electrical shock.
PMID 16470215·Eye (Lond)·2006
5-case
A rare cervical spine abnormality associated with neurofibromatosis.
PMID 17461326·Ceylon Med J·2006
5-case
Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours.
PMID 15809877·Cancer Chemother Pharmacol·2005
3-trial
Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation.
PMID 16353932·AAPS J·2005
6-review
Phase I and pharmacokinetic study of LY293111, an orally bioavailable LTB4 receptor antagonist, in patients with advanced solid tumors.
PMID 15939925·J Clin Oncol·2005
3-trial
Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies.
PMID 15534095·Clin Cancer Res·2004
3-trial
A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy.
PMID 15161679·Clin Cancer Res·2004
3-trial
Population pharmacokinetic model for daunorubicin and daunorubicinol coadministered with zosuquidar.3HCl (LY335979).
PMID 15045528·Cancer Chemother Pharmacol·2004
3-trial
A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979).
PMID 12848775·Br J Clin Pharmacol·2003
3-trial
Metal-bis[poly(pyrazolyl)borate] complexes. Electrochemical, magnetic, and spectroscopic properties and coupled electron-transfer and spin-exchange reactions.
PMID 12767201·Inorg Chem·2003
8-other
A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979).
PMID 12647011·Cancer Chemother Pharmacol·2003
8-other
Considerations in the design and development of transport inhibitors as adjuncts to drug therapy.
PMID 12535578·Adv Drug Deliv Rev·2003
6-review
A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies.
PMID 12473580·Clin Cancer Res·2002
3-trial
Comparison of manual versus ambulatory blood pressure measurements with pharmacokinetic-pharmacodynamic modeling of antihypertensive compounds: application to moxonidine.
PMID 10945312·Clin Pharmacol Ther·2000
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 622 W 168TH ST
NEW YORK, NY 10032 - Phone
- (212) 305-2179
Quick Facts
- NPI
- 1235925298
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 18
Are you this provider?
Claim Your Profile